Replies to post #99105 on Biotech Values

[DewDiligence]

Prezista is indeed on a tear: 2Q10 sales were +47% (!) year-over-year in constant currencies; the annualized run rate is $800M (http://finance.yahoo.com/news/Johnson-amp-Johnson-Reports-prnews-3944093197.html?x=0&.v=1 ).

We'll find out how Isentress is doing on July 30.